[
  {
    "ts": null,
    "headline": "Company News for Feb 11, 2026",
    "summary": "Companies in The News Are: SPOT,INCY,FISV,HAS",
    "url": "https://finnhub.io/api/news?id=974bcf02a03cb35a8a05cca9075294878a7ca61a055a6510f921929ed6309de2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770820140,
      "headline": "Company News for Feb 11, 2026",
      "id": 139046688,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Companies in The News Are: SPOT,INCY,FISV,HAS",
      "url": "https://finnhub.io/api/news?id=974bcf02a03cb35a8a05cca9075294878a7ca61a055a6510f921929ed6309de2"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $92",
    "summary": "RBC Capital  analyst Brian Abrahams   maintains Incyte (NASDAQ:INCY) with a Sector Perform and lowers the price target from $95 to $92.",
    "url": "https://finnhub.io/api/news?id=225ba662fa29b0446bbdd0640cf2ee39039b89adb07221c795a5b1953bef8ba1",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770815990,
      "headline": "RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $92",
      "id": 139058213,
      "image": "",
      "related": "INCY",
      "source": "Benzinga",
      "summary": "RBC Capital  analyst Brian Abrahams   maintains Incyte (NASDAQ:INCY) with a Sector Perform and lowers the price target from $95 to $92.",
      "url": "https://finnhub.io/api/news?id=225ba662fa29b0446bbdd0640cf2ee39039b89adb07221c795a5b1953bef8ba1"
    }
  },
  {
    "ts": null,
    "headline": "Stifel Maintains Buy on Incyte, Raises Price Target to $120",
    "summary": "Stifel  analyst Stephen Willey   maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $119 to $120.",
    "url": "https://finnhub.io/api/news?id=8183f9a93dbd10f15715da87348c6b0ce65a5cd4c53e1ace16b541bfb21a3a4d",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770809878,
      "headline": "Stifel Maintains Buy on Incyte, Raises Price Target to $120",
      "id": 139058214,
      "image": "",
      "related": "INCY",
      "source": "Benzinga",
      "summary": "Stifel  analyst Stephen Willey   maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $119 to $120.",
      "url": "https://finnhub.io/api/news?id=8183f9a93dbd10f15715da87348c6b0ce65a5cd4c53e1ace16b541bfb21a3a4d"
    }
  },
  {
    "ts": null,
    "headline": "Incyte: Why The Market Is Overreacting To A Guidance 'Miss'",
    "summary": "Incyte experienced an 8.2% sell-off after 2026 guidance appeared to miss consensus by $680M, but this was due to a royalties accounting nuance. Click to read.",
    "url": "https://finnhub.io/api/news?id=252dc8cf80a43f73090cb0f31afff135c10c0939c6b092020285355a1390ed62",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770807802,
      "headline": "Incyte: Why The Market Is Overreacting To A Guidance 'Miss'",
      "id": 139045349,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1893449171/image_1893449171.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Incyte experienced an 8.2% sell-off after 2026 guidance appeared to miss consensus by $680M, but this was due to a royalties accounting nuance. Click to read.",
      "url": "https://finnhub.io/api/news?id=252dc8cf80a43f73090cb0f31afff135c10c0939c6b092020285355a1390ed62"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo Maintains Equal-Weight on Incyte, Lowers Price Target to $101",
    "summary": "Wells Fargo  analyst Derek Archila   maintains Incyte (NASDAQ:INCY) with a Equal-Weight and lowers the price target from $107 to $101.",
    "url": "https://finnhub.io/api/news?id=85ae1d027d6a34908dd99624b098d3f3b5980c0c23ea9dd6b093c395a34c0f83",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770807354,
      "headline": "Wells Fargo Maintains Equal-Weight on Incyte, Lowers Price Target to $101",
      "id": 139058215,
      "image": "",
      "related": "INCY",
      "source": "Benzinga",
      "summary": "Wells Fargo  analyst Derek Archila   maintains Incyte (NASDAQ:INCY) with a Equal-Weight and lowers the price target from $107 to $101.",
      "url": "https://finnhub.io/api/news?id=85ae1d027d6a34908dd99624b098d3f3b5980c0c23ea9dd6b093c395a34c0f83"
    }
  },
  {
    "ts": null,
    "headline": "INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow",
    "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2025, with sales up 27.8% year on year to $1.51 billion. Its non-GAAP profit of $1.80 per share was 6.1% below analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=30b3f7efeaabbf9d0a2357d9b81edeadf63cb34ad3453d235a290545d959ff68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770787977,
      "headline": "INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow",
      "id": 139042740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2025, with sales up 27.8% year on year to $1.51 billion. Its non-GAAP profit of $1.80 per share was 6.1% below analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=30b3f7efeaabbf9d0a2357d9b81edeadf63cb34ad3453d235a290545d959ff68"
    }
  }
]